The collaboration focuses on conducting validation studies on Trucan's next-generation cancer diagnostic tests, which leverage advanced techniques such as next-generation sequencing and biomarker-driven diagnostics
Read More
In addition to revenue growth, HCG demonstrated robust gains across key financial indicators. For Q2, the company reported an adjusted EBITDA of Rs 1,042 million, marking a 21 per cent year-on-year increase with an EBITDA margin of 18.8 per cent
Read More
The approvals include bortezomib in the Philippines and carboplatin in Morocco
Read More-min_20240812163725_original_image_30.webp)
The event focused on addressing critical gaps in oncology care, emphasising the necessity of specialised care units for severe cancer-related conditions and the need for advanced expertise among onco-critical care professionals
Read More
